Medtronic plc (MDT) Earnings Call Transcripts

Medtronic plc's Latest Earnings Call - September 15, 2026

In the first quarter of fiscal year 2027, Medtronic plc reported a revenue growth of 7%, driven by strong performance in its cardiac rhythm management and surgical segments. The company raised its full-year revenue guidance to a midpoint of 7.5%, reflecting confidence in sustained growth from its core cardiovascular business and new product innovations. Management emphasized the positive impact of AI on procedural efficiency and patient outcomes, as well as the ongoing strength in procedure volumes despite macroeconomic challenges.

Reported metrics

Guidance from management

Medtronic raised its fiscal year 2027 revenue guidance to a midpoint of 7.5%, reflecting confidence in sustained growth from its core cardiovascular business and new product innovations.

What management said

I think we had announced that we would do it within a relatively on time frame after the first page. And yes, look, it's -- it's performing well. Q4 numbers for them were great. Q1 numbers were even better. The innovation cycle, every product launch is happening earlier than they expect. So they're on a role from an innovation perspective. So the business is doing great and it's the right time to do it. And again, th...

So first, I don't want to spoil the suspense so we've got a big Investor Day coming in December on the 10th and 11th, and that will be a key topic, right, because that's the #1 question we get from everyone is have you made that growth sustainable? But without spoiling everything, it's back to this concept of the base has become stronger CRM, CST surgical to innovation. And then we've got these 4 generational growth ...

What analysts pressed on

Analysts expressed concerns about the sustainability of the current growth rates, particularly in the context of future competitive pressures and market dynamics. There were questions regarding how the company plans to maintain its momentum in innovation and market share amidst increasing competition.

Main topics on the call

• Revenue Growth Acceleration — Medtronic achieved a revenue growth rate of 7% in Q1, with cardiac rhythm management growing at 15%. Management stated, "we've guided for sort of a midpoint for the full year, that's about 7.5%".
• AI Integration in Procedures — Management highlighted the role of AI in enhancing procedural workflows, stating, "AI detects 50% more polyps than a trained physician would with a naked eye". This integration is expected to improve patient outcomes and...
• Strong Cash Flow Performance — The company reported strong free cash flow performance in Q1, attributed to efficient accounts receivable management. Management noted, "Q1 was very strong" in cash collection, indicating robust financial health.
• Sustained Growth in Cardiac Ablation — The cardiac ablation segment lapped $2 billion in trailing 12-month revenue, with management expressing confidence in continued growth, stating, "we know that's going to continue to grow in the coming years for several r...

Read the full Medtronic plc transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 92 Medtronic plc earnings call transcripts on record, spanning January 13, 2020 to September 15, 2026. Based on this history, Medtronic plc reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MDT

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

92

First call

January 13, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly